Adam Seymour

Covance (United Kingdom)

Papers

2

Total Citations

70

H-Index

2

About

Dr. Adam Seymour is a leading researcher in the toxicological assessment of tobacco and nicotine products, with a primary focus on in vitro exposure systems. His major contributions center on developing and refining methodologies to evaluate the mutagenic and toxicological impacts of whole cigarette smoke and electronic-cigarette aerosols. Dr. Seymour’s most cited work (57 citations) provides a critical comparative assessment of e-cigarette aerosol and reference cigarette smoke using the Ames assay, demonstrating that e-cigarette aerosol collected matter was non-mutagenic under standard OECD 471 testing conditions. This study is foundational for understanding the reduced-risk potential of e-cigarettes. He further advanced the field by investigating multiple whole smoke dosimetry techniques using the VITROCELL® VC10® system, a key achievement that enables more physiologically relevant air-liquid and air-agar interface exposures. His work is instrumental in standardizing in vitro toxicology protocols for regulatory science. Dr. Seymour’s research is highly impactful for scientists and regulators seeking robust, reproducible methods to assess the safety of emerging nicotine delivery systems.

Research Focus

Key Achievements

2
H-Index
2
Papers
70
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
The mutagenic assessment of an electronic-cigarette and reference cigarette smoke using the Ames assay in strains TA98 and TA100
57 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Covance (United Kingdom)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago